Biological parameters and current status of European eel (Anguilla anguilla Linnaeus, 1758) from Asi River,Northeastern Mediterranean region,Turkey

The biological characteristics of eels from the Asi River, Turkey, were assessed between December 2017 and November 2018. Eels were sampled monthly using fyke nets (operated by professional fishermen), yielding a total of 509 specimens. Total length and weight were measured, sex, age and maturity stages (silver or yellow eel) were determined. Catch Per Unit Effort (CPUE) was calculated for both biomass per unit effort and numbers caught on a monthly and annual basis. The length-weight relationships (LWRs) of silver and yellow eel was W = 0.009*TL^3.22 (n = 262) and W = 0.0106*L^3.09 (n = 247), respectively. The age of the sampled fish ranged from year class II to VI. Von Bertalanffy growth parameters were estimated as L_∞=69.25 cm, K = 0.43 1/year, t₀= −0.41 and phi prime index ( ǿ )= 3.31 for all samples. The overall eel fishing mortality rate (F) was 0.31 year^-1, and the exploitation and survival rates of silver stage eels were estimated with 30% and 39%, respectively.     

An Integrated Workflow for DNA Methylation Analysis

The analysis of cytosine methylation provides a new way to assess and describe epigenetic regulation at a whole-genome level in many eukaryotes. DNA methylation has a demonstrated role in the genome stability and protection, regulation of gene expression and many other aspects of genome function and maintenance. BS-seq is a relatively unbiased method for profiling the DNA methylation, with a resolution capable of measuring methylation at individual cytosines. Here we describe, as an example, a workflow to handle DNA methylation analysis, from BS-seq library preparation to the data visualization. We describe some applications for the analysis and interpretation of these data. Our laboratory provides public access to plant DNA methylation data via visualization tools available at our “Next-Gen Sequence” websites (http://mpss.udel.edu), along with small RNA, RNA-seq and other data types.     

Strain and plastic composite support (PCS) selection for vitamin K (Menaquinone-7) production in biofilm reactors

Menaquinone-7 (MK-7), a subtype of vitamin K, has received a significant attention due to its effect on improving bone and cardiovascular health. Current fermentation strategies, which involve static fermentation without aeration or agitation, are associated with low productivity and scale-up issues and hardly justify the commercial production needs of this vitamin. Previous studies indicate that static fermentation is associated with pellicle and biofilm formations, which are critical for MK-7 secretion while posing significant operational issues. Therefore, the present study is undertaken to evaluate the possibility of using a biofilm reactor as a new strategy for MK-7 fermentation. Bacillus species, namely, Bacillus subtilis natto, Bacillus licheniformis, and Bacillus amyloliquifaciens as well as plastic composite, supports (PCS) were investigated in terms of MK-7 production and biofilm formation. Results show the possibility of using a biofilm reactor for MK-7 biosynthesis. Bacillus subtilis natto and soybean flour yeast extract PCS in glucose medium were found as the most potent combination for production of MK-7 as high as 35.5 mg/L, which includes both intracellular and extracellular MK-7.     

Gene therapy for sickle cell disease: An update

Sickle cell disease (SCD) is one of the most common life-threatening monogenic diseases affecting millions of people worldwide. Allogenic hematopietic stem cell transplantation is the only known cure for the disease with high success rates, but the limited availability of matched sibling donors and the high risk of transplantation-related side effects force the scientific community to envision additional therapies. Ex vivo gene therapy through globin gene addition has been investigated extensively and is currently being tested in clinical trials that have begun reporting encouraging data. Recent improvements in our understanding of the molecular pathways controlling mammalian erythropoiesis and globin switching offer new and exciting therapeutic options. Rapid and substantial advances in genome engineering tools, particularly CRISPR/Cas9, have raised the possibility of genetic correction in induced pluripotent stem cells as well as patient-derived hematopoietic stem and progenitor cells. However, these techniques are still in their infancy, and safety/efficacy issues remain that must be addressed before translating these promising techniques into clinical practice.